Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Her-2 Negative Metastatic Breast Cancer
• Age: Between 18 years - 90 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Histologically confirmed adenocarcinoma of the breast that is either TNBC or HER-2 negative.
  2. Received 0-2 lines of cytotoxic chemotherapy for metastatic breast cancer endocrine therapy and/or targeted therapy is allowed.
  3. Must have less than or equal to Grade 1 pre-existing peripheral neuropathy (as per CTCAE).

  
  

You may not be eligible for this study if the following are true:

• 1. Hypersensitivity to pembrolizumab or any of its excipients.
  2. Has a known additional malignancy that progressed or required treatment within the last five years (exception:  basal cell carcinoma of the skin or squamous cell carcinoma of the skin or in situ cervical cancer)
  3. Patients with known active central nervous system metastases and/or carcinomatous meningitis
  4. Taxane therapy within 3 months.